BioSpace News Archive

Renovion, Inc. today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating ARINA-1, an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.

Theratechnologies Inc. today presented preclinical data that demonstrate the potential utility of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902) -- both as a single agent and in combination with other anticancer therapies -- in targeting tumors that express the sortilin (SORT1) receptor.

Bloomage Biotech, an international pioneer in biotechnology and biomaterials, demonstrated its industry leadership with its cutting-edge bioactive ingredients at the 2023 International Consumer Products Expo held in Haikou from April 10th to 15th.

Elevar Therapeutics, Inc. today announced that a comparative biochemical analysis identified rivoceranib, its lead investigational drug, as the most selective vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor when compared with other tyrosine kinase inhibitors (TKIs) with known activity against VEGFR-2.

Global biotechnology leader CSL Behring today announced the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid).

Primmune Therapeutics today presented new clinical data from a first-in-human, Phase 1 study evaluating PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the American Association of Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Orum Therapeutics today announced new preclinical data for three of Orum’s therapeutic programs: ORM-5029, which is a proprietary GSPT1 degrader conjugated to HER2-targeting antibody pertuzumab; ORM-6151, which delivers GSPT1 degrader to CD33+ tumors; and its new immuno-oncology program for a Cbl-b inhibitor (Cbl-bi) conjugated to anti-PD-1 antibody pembrolizumab.

Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device control, today announced the results of recent clinical trial conducted by researchers at the Lewis Katz School of Medicine at Temple University’s MDA/ALS Center of Hope.

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission (“SEC”) on April 14, 2023.

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.